Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HEMICLOR vs Enoxaparin
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hemichlor (HEMICLOR) is a brand name for a combination product containing chlorpheniramine and pseudoephedrine. Chlorpheniramine is a first-generation antihistamine that antagonizes histamine at H1 receptor sites, reducing allergic symptoms. Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.
Enoxaparin is a low molecular weight heparin that binds to antithrombin III, potentiating its inhibition of factor Xa and thrombin. It has a higher ratio of anti-factor Xa to anti-factor IIa activity compared to unfractionated heparin.
Relief of symptoms associated with seasonal and perennial allergic rhinitis, including nasal congestion, sneezing, rhinorrhea, and pruritus,Off-label: Adjunctive treatment for acute sinusitis and common cold symptoms
Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement, knee replacement, or medical patients at risk,Treatment of acute DVT with or without pulmonary embolism,Treatment of unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI) in combination with aspirin,Prophylaxis of ischemic complications in patients with acute ST-segment elevation myocardial infarction (STEMI) managed medically or with percutaneous coronary intervention
50-100 mg intravenously every 6 hours or 100 mg orally every 12 hours.
1 mg/kg subcutaneously every 12 hours for treatment of venous thromboembolism; 40 mg subcutaneously once daily for prophylaxis of venous thromboembolism.
Terminal elimination half-life 18–24 hours in normal renal function; prolonged to 36–48 hours in moderate renal impairment (Cr Cl 30–50 m L/min); adjust dosing interval in renal disease.
Terminal elimination half-life is 4.5 hours after a single subcutaneous dose, and 7 hours after repeated dosing, reflecting accumulation. Mean half-life is approximately 4-5 hours in healthy volunteers.
Chlorpheniramine is extensively metabolized in the liver via CYP450 enzymes, primarily CYP2D6, and excreted renally as metabolites. Pseudoephedrine is partially metabolized in the liver by N-demethylation and excreted largely unchanged in urine; its metabolism is not significantly enzyme-dependent.
Enoxaparin is primarily metabolized in the liver by desulfation and depolymerization; elimination is via renal excretion of low molecular weight fragments.
Primarily renal (85–90% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal < 5%.
Renal elimination accounts for 40% of the administered dose, with the remainder undergoing hepatic metabolism and/or distribution. Biliary/fecal excretion is minimal (<5%).
70–80% (primarily to albumin).
Enoxaparin is highly protein bound (>80%) to antithrombin III and other plasma proteins.
0.3–0.5 L/kg (indicates moderate tissue distribution).
Volume of distribution is approximately 0.15-0.25 L/kg (4-6 L total), indicating limited extravascular distribution, primarily confined to the vascular compartment.
Oral: 40–60% (due to first-pass metabolism; food may reduce absorption).
Subcutaneous: Approximately 92-100% bioavailability based on anti-Xa activity. Oral: negligible due to poor absorption.
GFR 30-50 m L/min: 50 mg IV every 12h or 50 mg PO every 24h; GFR 10-29 m L/min: 50 mg IV every 24h or 25 mg PO every 24h; GFR <10 m L/min: 25 mg IV every 48h or avoid use.
For Cr Cl <30 m L/min: reduce dose to 1 mg/kg subcutaneously once daily for treatment; for prophylaxis, reduce to 30 mg subcutaneously once daily.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
No specific dose adjustment recommended; use with caution in severe hepatic impairment.
5-10 mg/kg IV every 6h, max 100 mg/dose.
For treatment of venous thromboembolism: 1 mg/kg subcutaneously every 12 hours. For prophylaxis: 0.5 mg/kg subcutaneously every 12 hours. Dose adjustments based on anti-Xa monitoring.
Start at lower end of dosing range (50 mg IV every 12h or 50 mg PO every 24h) due to reduced renal function and increased sensitivity.
Increased risk of bleeding; consider lower initial doses and monitor renal function and bleeding closely. No specific dose adjustment solely based on age.
No FDA black box warning is present for HEMICLOR.
Spinal or epidural hematomas, including subsequent paralysis, may occur in patients receiving enoxaparin who are undergoing neuraxial anesthesia or spinal puncture. Risk is increased by use of indwelling epidural catheters, concomitant use of drugs affecting hemostasis, history of traumatic or repeated epidural or spinal puncture, or spinal deformity.
Cardiovascular effects: Use with caution in patients with hypertension, ischemic heart disease, or arrhythmias,CNS depression: Chlorpheniramine may cause sedation; avoid concurrent use with alcohol or other CNS depressants,Monoamine oxidase inhibitor (MAOI) interaction: Concomitant use with MAOIs or within 14 days of discontinuation can precipitate hypertensive crisis,Urinary retention: Use cautiously in patients with prostatic hypertrophy or bladder neck obstruction,Photosensitivity: Chlorpheniramine may increase risk of photosensitivity reactions
Increased risk of bleeding, especially in patients with renal impairment, uncontrolled hypertension, or history of gastrointestinal bleeding; thrombocytopenia (including heparin-induced thrombocytopenia); elevated serum potassium levels (hyperkalemia); use in pregnancy and lactation; elderly patients (increased bleeding risk).
Hypersensitivity to chlorpheniramine, pseudoephedrine, or any component,Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of MAOI therapy,Severe hypertension or severe coronary artery disease,Narrow-angle glaucoma,Urinary retention,Breastfeeding (relative contraindication due to pseudoephedrine excretion)
Active major bleeding; history of heparin-induced thrombocytopenia (HIT); hypersensitivity to enoxaparin or heparin; patients undergoing regional anesthesia with known bleeding risk; severe uncontrolled hypertension; bacterial endocarditis; conditions with increased risk of hemorrhage (e.g., recent surgery, trauma, peptic ulcer disease, hemorrhagic stroke).
Avoid alcohol and grapefruit juice. Take with food to reduce gastrointestinal upset. Limit caffeine intake as it may worsen anxiety or gastrointestinal symptoms.
No specific food interactions. Vitamin K-rich foods (leafy greens) do not significantly affect LMWH, in contrast to warfarin. Avoid excessive alcohol intake due to increased bleeding risk. Do not take supplements like fish oil, ginkgo, or ginger without consulting prescriber due to antiplatelet effects.
Hemichlor (hydrochlorothiazide) is contraindicated in pregnancy due to risk of fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances. First trimester: associated with neural tube defects in animal studies and possible oligohydramnios. Second/third trimester: risk of fetal bradycardia, hyponatremia, hypokalemia, and decreased placental perfusion.
Enoxaparin does not cross the placenta and is not teratogenic. No increased risk of fetal malformations has been observed in human studies. First trimester: no known risk. Second and third trimesters: no known risk, though there is a risk of maternal hemorrhage that could affect the fetus.
Hydrochlorothiazide is excreted in breast milk in low concentrations. M/P ratio approximately 0.04-0.06. No adverse effects reported in infants, but may suppress lactation at high doses. Use with caution, monitor infant for electrolyte disturbances.
Enoxaparin is not detected in breast milk due to its high molecular weight and protein binding; therefore, it is considered compatible with breastfeeding. M/P ratio: not applicable (not measurable).
Pregnancy increases volume of distribution and renal clearance of hydrochlorothiazide, potentially reducing peak serum concentration. However, due to fetal risks, thiazide diuretics are generally avoided in pregnancy. If essential, use lowest effective dose and monitor maternal/fetal status closely. No specific dose adjustment studies exist.
Pregnancy increases clearance of enoxaparin; dose adjustments may be needed based on anti-Xa monitoring. Generally, dose adjustments are not routinely required for standard prophylactic doses, but therapeutic doses may need to be increased (e.g., weight-based dosing) and monitored. Avoid use in patients with active major bleeding or known hypersensitivity.
HEMICLOR contains clidinium bromide (quaternary ammonium anticholinergic) and chlordiazepoxide (benzodiazepine). Monitor for anticholinergic side effects (dry mouth, blurred vision, urinary retention, constipation). Avoid use in patients with narrow-angle glaucoma, obstructive uropathy, or myasthenia gravis. Chlordiazepoxide may cause dependence; limit duration to 4-8 weeks. Use with caution in elderly due to increased sensitivity to anticholinergic effects and risk of falls.
Enoxaparin is a low molecular weight heparin (LMWH) that preferentially inhibits factor Xa over thrombin. Monitor anti-factor Xa levels in patients with renal impairment (Cr Cl <30 m L/min) and in pregnant women. Protamine sulfate partially reverses anticoagulation (approximately 60% anti-factor Xa activity). Avoid intramuscular injections due to hematoma risk. Epidural/spinal anesthesia increases risk of spinal hematoma; remove catheter at least 12 hours after last dose (or 24 hours if therapeutic dosing). Adjust dose for moderate renal impairment (Cr Cl 30-50 m L/min) in treatment of VTE or unstable angina.
Take exactly as prescribed; do not increase dose or stop abruptly.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Avoid alcohol and other CNS depressants.,Report any signs of urinary retention, severe constipation, or blurred vision.,Do not share with others; risk of dependence.,Store at room temperature away from moisture and heat.
Do not skip doses; take at the same time each day.,Rotate injection sites (left and right sides of abdomen) and do not rub the site after injection.,Watch for signs of bleeding: unusual bruising, blood in urine/stool, prolonged bleeding from cuts, or bleeding from gums.,Seek emergency care if you have signs of a spinal blood clot (back pain, numbness/weakness in legs, loss of bowel or bladder control).,Avoid aspirin, NSAIDs (ibuprofen, naproxen), and other blood thinners unless prescribed by your doctor.,Tell all healthcare providers including dentists that you are taking enoxaparin.,Do not drive or operate heavy machinery if you feel dizzy or weak from bleeding.,Store enoxaparin at room temperature; do not freeze.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HEMICLOR vs Enoxaparin, answered by our medical review team.
HEMICLOR is a Electrolyte Supplement that works by Hemichlor (HEMICLOR) is a brand name for a combination product containing chlorpheniramine and pseudoephedrine. Chlorpheniramine is a first-generation antihistamine that antagonizes histamine at H1 receptor sites, reducing allergic symptoms. Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.. Enoxaparin is a Low Molecular Weight Heparin that works by Enoxaparin is a low molecular weight heparin that binds to antithrombin III, potentiating its inhibition of factor Xa and thrombin. It has a higher ratio of anti-factor Xa to anti-factor IIa activity compared to unfractionated heparin.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HEMICLOR and Enoxaparin depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HEMICLOR is: 50-100 mg intravenously every 6 hours or 100 mg orally every 12 hours.. The standard adult dose of Enoxaparin is: 1 mg/kg subcutaneously every 12 hours for treatment of venous thromboembolism; 40 mg subcutaneously once daily for prophylaxis of venous thromboembolism.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HEMICLOR and Enoxaparin in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HEMICLOR is classified as Category C. Hemichlor (hydrochlorothiazide) is contraindicated in pregnancy due to risk of fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances. First trimester: associated . Enoxaparin is classified as Category A/B. Enoxaparin does not cross the placenta and is not teratogenic. No increased risk of fetal malformations has been observed in human studies. First trimester: no known risk. Second a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.